Exhibit 10gg

                          DISTRIBUTORSHIP AGREEMENT

This Agreement is entered into this 20th day of November, 1996, by and 
between HEMAGEN DIAGNOSTICS, INC., a corporation organized and existing 
under the laws of the State of Delaware, U.S.A. and having its principal 
place of business at 40 Bear Hill Road, Waltham, Massachusetts, U.S.A. 
(hereinafter referred to as "HEMAGEN"), and SCHIAPPARELLI BIOSYSTEMS B.V., a 
corporation organized and existing under the laws of Holland and having its 
principal place of business at Pompmolenlaan 24, 3447 GK Woerden, P.O. Box 
497 - 3440 AL Woerden, The Netherlands (hereinafter referred to as 
"DISTRIBUTOR").

                                  RECITALS

      WHEREAS, DISTRIBUTOR desires to distribute certain products offered 
for sale by HEMAGEN; and

      WHEREAS, HEMAGEN desires to engage DISTRIBUTOR to market and sell said 
products in the territory defined below; and

      WHEREAS, DISTRIBUTOR and HEMAGEN desire to enter into a business 
relationship pursuant to the terms of this Agreement; and

      WHEREAS, DISTRIBUTER has represented to HEMAGEN that it has the 
necessary facilities, personnel to commercially market and sell the 
products.

      WHEREAS, HEMAGEN has represented to DISTRIBUTOR that it has the 
necessary facilities, personnel, and technology to commercially manufacture 
the products.

      NOW, THEREFORE, in consideration of the above recitals, and in 
consideration of the mutual covenants and agreements hereinafter set forth, 
HEMAGEN and DISTRIBUTOR do hereby agree as follows:

                                   AGREEMENT

Article 1. Definitions

1.1   "PRODUCT(s)" means and includes certain of HEMAGEN's complete test 
      kits, as set forth in Appendix A and as amended from time to time by 
      mutual written agreement of the parties.

1.2.  "AFFILIATE" means any entity directly or indirectly controlling, 
      controlled by, or under common control with, a party hereto.  
      "Control", as used in this definition, means the ownership of fifty 
      percent or more of the party in question.

1.3.  "TERRITORY" means the Countries listed in the Attached Appendix 1.3. 

1.4.  "NON-EXCLUSIVE TERRITORY" means France , Spain, Philippines, Russia 
      and Austria.  Austria shall only include the VIRGO products and France 
      shall only include the ENA ELISA products.

Article 2. Term

2.1   The initial term of this Agreement shall be for a period of two (2) 
      years unless terminated as provided in Article 13.  This Agreement 
      shall automatically continue to be in effect after the initial term 
      for successive twelve-month periods unless it is terminated by either 
      party as provided in Article 13 or written notice of non-renewal is 
      given by either party to the other at least three (3) months prior to 
      the expiration of the initial term or at least three (3) months prior 
      to the expiration of any successive twelve-month term.

Article 3. Exclusive Sale and Distribution Rights

3.1.  Distribution Rights. Subject to the terms and conditions hereinafter 
      set forth, DISTRIBUTOR shall have the exclusive right to market, sell 
      and distribute the PRODUCTs in the TERRITORY under the HEMAGEN label 
      or under its own label and DISTRIBUTOR shall have the non-exclusive 
      right to market, sell and distribute the PRODUCTs in the NON-EXCLUSIVE 
      TERRITORY under the HEMAGEN label or under its own label, so long as 
      the PRODUCTs are identified as being manufactured by HEMAGEN.  
      DISTRIBUTOR shall not have the right to enter into any agreements or 
      contracts which are binding upon HEMAGEN unless prior written approval 
      is given by HEMAGEN. 

3.2   Exclusivity. During the term of this Agreement and any extensions 
      thereto, HEMAGEN will not sell, offer to sell or distribute PRODUCTs 
      under HEMAGEN's label to any person or entity within the TERRITORY.  
      HEMAGEN shall have the right to sell, offer to sell or distribute 
      PRODUCTs under HEMAGEN's label to any person or entity within the NON-
      EXCLUSIVE TERRITORY.  DISTRIBUTOR's right to sell, offer to sell or 
      distribute PRODUCTS in the NON-EXCLUSIVE TERRITORY may be terminated 
      as provided in Paragraph 13.7.  In addition, DISTRIBUTOR's exclusive 
      right to sell, offer to sell or distribute PRODUCTS in the EXCLUSIVE 
      TERRITORY may be terminated as provided in Paragraph 3.4.

3.3   Minimum Purchases. In order to retain its exclusive distribution 
      rights in the TERRITORY as stated in this Article 3, DISTRIBUTOR must 
      purchase the minimum annual quantities of PRODUCT set forth in 
      Appendix B. 

3.4   Termination of Exclusive Rights.  The parties acknowledge that 
      DISTRIBUTOR currently sells in the TERRITORY, competitive ELISA 
      products to those manufactured by HEMAGEN.  HEMAGEN shall have the 
      right, in its sole discretion, terminate DISTRIBUTOR's exclusive 
      distribution rights when a third party distributor indicates a desire 
      to sell both the VIRGO IFA and VIRGO ELISA products.  DISTRIBUTOR will 
      retain non-exclusive rights to sell in the country(ies) within the 
      TERRITORY for the remaining term of the Agreement, provided the 
      Agreement is not terminated for as set forth in the Agreement.

Article 4. Terms and Conditions of Sale

4.1.  HEMAGEN's terms and conditions of sale (defined in Appendix B and in 
      other provisions of this Agreement) will apply to all purchases by 
      DISTRIBUTOR, notwithstanding any variation as may appear on any 
      purchase order submitted by DISTRIBUTOR.  All purchase orders and 
      amendments thereto must be in writing, and should contain (I) quantity 
      of at least the Minimum PRODUCT Order per shipment stated in Appendix 
      B, (ii) date of requested delivery, and (iii) preferred shipping 
      instructions, if any.

4.2.  Shipping date.  HEMAGEN shall use its best efforts to ship all such 
      orders so that the PRODUCTs arrive on the requested delivery date.  
      HEMAGEN shall promptly notify DISTRIBUTOR of any anticipated delays in 
      shipping.

4.3.  Deliveries.  All deliveries shall be made F.O.B. HEMAGEN's plant in 
      Waltham, Massachusetts or F.O.B. HEMAGEN's plant in Columbia, Maryland 
      (depending upon where the PRODUCTs are manufactured).  For purposes of 
      this Agreement, F.O.B. shall also mean E.X.W. when ocean shipping is 
      not utilized.  Title and risk of loss will transfer from HEMAGEN to 
      DISTRIBUTOR upon delivery of the PRODUCT to the F.O.B. point.  Freight 
      and insurance charges shall be borne by DISTRIBUTOR.

4.4.  Purchase Price.  A current price list is attached to this Agreement as 
      Appendix C.  This price list shall remain in effect without change for 
      twelve (12) months after the date of this Agreement.  HEMAGEN will 
      notify DISTRIBUTOR of changes to its price list at least sixty (60) 
      days prior to the effective date of any price changes.   All prices 
      quoted by HEMAGEN are subject to the addition of all taxes and duties 
      which are now or may be levied or assessed relating to the shipment or 
      delivery of the PRODUCTs to the DISTRIBUTOR and shall be paid by 
      DISTRIBUTOR.  Any taxes which HEMAGEN is obligated to collect shall be 
      paid by DISTRIBUTOR upon payment of the purchase price for the 
      PRODUCT, or in lieu of this, DISTRIBUTOR shall provide to HEMAGEN a 
      duty or tax exemption certificate acceptable to the appropriate taxing 
      authorities.

Article 5. Non-competition

5.1.  Competing Products.  DISTRIBUTOR agrees that during the term of this 
      Agreement and any extensions thereto, neither it nor any AFFILIATE 
      will market or sell any goods or diagnostic tests which is competitive 
      with a PRODUCT.

Article 6. Cooperation/Best Efforts

6.1.  Best Efforts. DISTRIBUTOR will use its best efforts to sell the 
      PRODUCTs and will not perform any acts that might jeopardize the 
      reputation of the PRODUCTs or of HEMAGEN.  HEMAGEN will not perform 
      any acts that might jeopardize the reputation of the PRODUCTs or of 
      DISTRIBUTOR.

6.2.  Cooperation.  The spirit of this Agreement is that the two parties 
      shall cooperate to the fullest extent possible.

Article 7   Performance Standards

7.1.  PRODUCT Acceptance.  DISTRIBUTOR shall have the right (at its own 
      cost) to take random samples of PRODUCTs delivered by HEMAGEN for 
      analyzing purposes.  Should the result of an analysis of any such 
      sample deviate from the PRODUCT specifications or quality control 
      standards, HEMAGEN shall be notified and provided with samples of the 
      PRODUCTs tested.  If, following a review of the test results and after 
      conducting its own tests of the sample, HEMAGEN agrees that such 
      sample does not conform to said specifications or quality control 
      standards, HEMAGEN shall provide DISTRIBUTOR, free of any additional 
      charge, with new deliveries of the same quantity of the PRODUCTs as 
      the one from which the random sample were taken.  DISTRIBUTOR shall 
      return, at HEMAGEN's expense, the particular lot or shipment of the 
      PRODUCT which does not comply with the aforesaid specifications or 
      quality control standards. In the event HEMAGEN finds that the test 
      results of the PRODUCT in question comply with specifications and 
      quality control standards, then replacement, if deemed necessary by 
      DISTRIBUTOR, shall be at DISTRIBUTOR's expense. HEMAGEN further 
      warrants that all test results will be made available to DISTRIBUTOR.  

7.2.  PRODUCT Modification.  Throughout the term of this Agreement, HEMAGEN 
      may desire to make certain changes in the performance or appearance of 
      the PRODUCTs.  HEMAGEN shall notify DISTRIBUTOR of all such changes in 
      performance or appearance.  In any event, best efforts shall be made 
      to deliver such notification at least ninety (90) days prior to the 
      desired or expected implementation date in the event that such change 
      requires a re-filing for FDA (U.S. Food and Drug Administration) 
      regulatory clearance or a similar re-filing with any other regulatory 
      agency. 

Article 8. Duties of DISTRIBUTOR

8.1.  Trade and Advertising Practices.  DISTRIBUTOR agrees that it shall not 
      engage in any unfair trade practices or make any false or misleading 
      statements or representations in its advertising, printed material, or 
      otherwise with respect to HEMAGEN and/or the PRODUCTs and/or any 
      trademark and/or any other proprietary property of HEMAGEN.  
      DISTRIBUTOR, at DISTRIBUTOR's cost, agrees to correct and/or change 
      any such statements which HEMAGEN considers materially objectionable.  
      If DISTRIBUTOR advertises the PRODUCTs, such advertising shall be in 
      compliance with all applicable state, federal and international laws 
      and regulations.

8.2.  Export Issues.  DISTRIBUTOR shall assist HEMAGEN with various United 
      States export issues such as licensing.

8.3.  Licenses and Permits.  DISTRIBUTOR, at its own expense, shall be 
      responsible for obtaining all licenses and permits required by any 
      governmental authority, regulatory or otherwise, in order to import 
      the PRODUCTs into the TERRITORY and the NON-EXCLUSIVE TERRITORY or 
      sell the PRODUCTs in the TERRITORY and the NON-EXCLUSIVE TERRITORY.  
      DISTRIBUTOR agrees, at its own expense, to comply with all applicable 
      laws, regulations and orders governing the sale, disposition, shipment 
      and import of the PRODUCTs and to purchase and maintain in effect all 
      licenses, permits and authorizations from all government agencies as 
      may be necessary to perform its obligations hereunder.  Unless such 
      information is proprietary, HEMAGEN will supply DISTRIBUTOR with any 
      required information which DISTRIBUTOR shall reasonably request for 
      the sole purpose of obtaining licenses and permits. 

8.4.  Regulatory Approval.  To the extent required by applicable laws and 
      prior to shipment of the PRODUCTs, DISTRIBUTOR agrees to submit the 
      PRODUCTs for approval of the applicable regulatory authorities in the 
      TERRITORY and the NON-EXCLUSIVE TERRITORY.  Unless such information is 
      proprietary HEMAGEN shall provide DISTRIBUTOR with all technical and 
      other data developed by HEMAGEN in support of DISTRIBUTOR's regulatory 
      submission as soon as such data is, or has been, developed by HEMAGEN. 

8.5.  Compliance with Laws.  DISTRIBUTOR agrees to comply at all times with 
      all applicable laws of the United States, including but not limited to 
      the controls of re-exports of U.S.-Origin commodities and technical 
      data and the provisions of the Foreign Corrupt Practices Act, and 
      similar laws of the U.S. and/or any other country.

8.6.  PRODUCT Record Keeping.  DISTRIBUTOR agrees to maintain and when 
      required by law or any governmental agency, provide to HEMAGEN 
      information that lists DISTRIBUTOR's lot numbers of each PRODUCT with 
      corresponding HEMAGEN lot numbers (if different), where each lot was 
      shipped, who purchased it and the address of the customer. 
 
8.7.  Conditions For Resale.  DISTRIBUTOR shall be free to determine all 
      terms and conditions of resale of the PRODUCTs purchased from HEMAGEN.  
      Any additional warranty offered by DISTRIBUTOR or any modification of 
      HEMAGEN's limited warranty without express written approval or 
      concurrence by HEMAGEN shall be the sole responsibility of 
      DISTRIBUTOR, and DISTRIBUTOR shall indemnify HEMAGEN for any costs, 
      losses or damage incurred by its as a result of any such additional 
      warranty or modification.

Article 9. Duties of HEMAGEN

9.1.  Technical Assistance and Training.  HEMAGEN shall provide training and 
      technical assistance to DISTRIBUTOR necessary for the marketing of the 
      PRODUCTs. Technical assistance and training shall be provided by 
      HEMAGEN at no charge to DISTRIBUTOR except that if the training is 
      performed at DISTRIBUTOR's premises, HEMAGEN's personnel shall be 
      reimbursed by DISTRIBUTOR for their reasonable expense of travel, 
      meals, and lodging.  All technical assistance and training shall be 
      performed at times convenient to both parties.

9.2.  Instructions.  HEMAGEN shall, at HEMAGEN's expense, provide 
      DISTRIBUTOR with written instructions (in English) relating to the 
      PRODUCT(s) use, and with such amendments thereto as subsequently 
      become available.  However, DISTRIBUTOR shall be responsible, at 
      DISTRIBUTOR's cost, for having such instructions translated into any 
      language necessary to complete its obligations hereunder.

9.3.  Distributor Assistance.  HEMAGEN shall promptly respond to 
      DISTRIBUTOR's inquiries and provide technical support to DISTRIBUTOR 
      regarding the sale, use or operation of PRODUCTs. 

9.4.  Promotional Materials.  HEMAGEN shall furnish DISTRIBUTOR, free of 
      charge, with promotional materials, samples of PRODUCTs and technical 
      data, the selection and quantity of which shall be determined at 
      HEMAGEN's sole discretion. 

9.5.  Export Licenses.  HEMAGEN shall be responsible for obtaining all 
      export licenses required by the United States Government to export 
      PRODUCTs to the TERRITORY and the NON-EXCLUSIVE TERRITORY.

9.6.  Good Manufacturing Practices.  HEMAGEN shall manufacture PRODUCTs in 
      accordance with good manufacturing practices required by the FDA.

Article 10  Trademarks, Patents, Intellectual Property, and Indemnification

10.1. Right of Use.  DISTRIBUTOR may use any of DISTRIBUTOR's trademarks, 
      trade names, service marks, copyrights or logos of DISTRIBUTOR's 
      choice relating to the marketing or sale of the PRODUCTs.  All such 
      use will be for the benefit of DISTRIBUTOR, and HEMAGEN will acquire 
      no ownership in such marks, or trade names, copyrights, logos or 
      labels by virtue of such use.

10.2. Patents and Trademarks.  DISTRIBUTOR acknowledges and agrees that 
      nothing herein shall give DISTRIBUTOR any right, title or interest in 
      or license to use any HEMAGEN patent, trademark, service mark, trade 
      name, copyright, or know-how, except as expressly set forth herein.  
      DISTRIBUTOR may use HEMAGEN's trademarks, trade names or service marks 
      only in connection with the sale, advertising and promotion of the 
      PRODUCT.  DISTRIBUTOR shall be entitled to use HEMAGEN's trademarks, 
      trade names or service marks only during the term of this Agreement.

10.3. Indemnification.  DISTRIBUTOR agrees to defend, indemnify and hold 
      HEMAGEN harmless from and against all loss, liability and expense 
      (including attorney's fees, settlements, litigation costs, and costs 
      of appeal) resulting from the acts or omissions of DISTRIBUTOR or its 
      agents with respect to its handling, marketing or selling of the 
      PRODUCTs including, but not limited to, DISTRIBUTOR's sale of the 
      PRODUCTs for use in humans or clinical diagnosis or analysis, 
      DISTRIBUTOR's fraud or misrepresentation in the use, distribution, or 
      sale of the PRODUCTs, or DISTRIBUTOR's mishandling of the PRODUCTs or 
      DISTRIBUTOR's failure to comply with the PRODUCTs' registration 
      requirements in any jurisdiction in which DISTRIBUTOR sells the 
      PRODUCTs.  Likewise, HEMAGEN agrees to defend, indemnify and hold 
      DISTRIBUTOR harmless from all and against all loss, liability and 
      expense (including attorney's fees, settlements, litigation costs, and 
      costs of appeal) resulting from the acts or omissions of HEMAGEN or 
      its agents with respect to its handling or manufacturing of the 
      PRODUCTs including but not limited to HEMAGEN's fraud or 
      misrepresentation in the manufacture or sale of the PRODUCTs, or 
      HEMAGEN's mishandling of the PRODUCTs.

10.4. Indemnification Notice.  Each party shall give prompt notice of any 
      claim, loss or liability for which such party seeks defense and 
      indemnification.  If either party wishes to enter the defense of a 
      suit brought pursuant to the indemnification sections of this 
      Agreement being defended by the other party, such party may do so at 
      its own cost.  The control of such case shall remain with the 
      indemnifying party unless otherwise agreed to in writing.

10.5. Settlement Notice.  If either party wishes to settle a case for which 
      the other party is liable for indemnification, the party wishing to 
      settle shall first obtain the written approval of the indemnifying 
      party.

10.6. Insurance.  Each party will keep in force during the term of this 
      Agreement all customary forms of insurance, including but not limited 
      to product liability insurance, in such amounts as are prudently 
      required. 

10.7. Infringement.  HEMAGEN shall undertake at HEMAGEN's own expense the 
      defense of any suit or action for infringement of HEMAGEN's patents 
      brought against DISTRIBUTOR, which suit or action results from the 
      sale of any PRODUCTs, provided that DISTRIBUTOR shall have promptly 
      advised HEMAGEN in writing of each notice or claim of infringement 
      received by DISTRIBUTOR and of the commencement of the suit or action.  
      HEMAGEN shall hold DISTRIBUTOR harmless from damages or other sums 
      which may be assessed or may become payable under any final decree or 
      judgment in any such suit or action or under any settlement thereof.  
      HEMAGEN shall have sole charge and direction of the defense of any 
      such suit or action and of all negotiations for such settlement, but 
      shall use commercial reasonableness and shall consult with DISTRIBUTOR 
      with regard to the defense or settlement of any such suit or action.  
      DISTRIBUTOR shall be obligated to render all reasonable assistance 
      which may be required by HEMAGEN at HEMAGEN's expense.  DISTRIBUTOR 
      may retain counsel of its own selection and at its own expense to 
      advise and consult with HEMAGEN's counsel.  HEMAGEN may not settle any 
      suit or action without the consent of DISTRIBUTOR, if by such 
      settlement DISTRIBUTOR is obligated to make any monetary payment, to 
      part with any property or interest therein, to assume any obligation 
      or to be subject to any injunction.  The parties agree that if the 
      PRODUCTs supplied by HEMAGEN are found to be infringing on a third-
      party patent, HEMAGEN will negotiate in good faith with the third 
      party to obtain a license to use the third party's technology and, if 
      HEMAGEN fails to obtain such a license, or if HEMAGEN is subject to a 
      permanent injunction, then DISTRIBUTOR shall have the right to either 
      terminate this Agreement by giving written notice of termination to 
      HEMAGEN, and return for full credit all inventory on hand, or 
      negotiate with the infringed party for such a license. HEMAGEN's 
      indemnification resulting from any infringement on third party patent 
      shall exclude DISTRIBUTOR's costs involved in negotiation with any 
      infringed party for such a license. 

Article 11  Limited Warranty

11.1. Shelf Life Warranty.  The PRODUCT shall have a shelf life, at the time 
      of shipment by HEMAGEN, as specified in Appendix A.  HEMAGEN shall not 
      be liable for any variance from specifications or any failure to 
      satisfy the shelf life requirement to the extent such variance is 
      caused by conditions or events occurring after shipment from HEMAGEN's 
      plant.

11.2. PRODUCT Specification, Defective PRODUCT Notice and PRODUCT 
      Complaints.  HEMAGEN warrants that, at the time of delivery to 
      DISTRIBUTOR, all PRODUCTs supplied by HEMAGEN shall meet PRODUCT 
      specifications.  Either party shall immediately notify the other party 
      in writing should it become aware of any defect or condition that may 
      render the PRODUCT(s) supplied by HEMAGEN in violation of the U.S. 
      Food, Drug and Cosmetic Act, or of a similar law of any jurisdiction 
      where the PRODUCT is sold.  The parties shall share with each other 
      all data on the PRODUCT complaints including, but not limited to, 
      complaints or information regarding performance and/or allegations or 
      reports of any negative effect from the use or misuse of the PRODUCTs 
      as soon as such data is available.  Each party will assist the other 
      in resolving DISTRIBUTOR's customers' complaints.  However, 
      DISTRIBUTOR shall have sole responsibility and authority to interact 
      directly with DISTRIBUTOR's customers in the resolution of such 
      complaints, and HEMAGEN shall be responsible only for interacting with 
      DISTRIBUTOR in such matters.

11.3. Warranties.  THE WRITTEN WARRANTIES OF HEMAGEN IN THIS ARTICLE 11 ARE 
      THE SOLE EXCLUSIVE WARRANTIES PROVIDED TO DISTRIBUTOR AND TO CONSUMERS 
      AND ARE IN LIEU OF ALL OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, 
      IMPLIED OR STATUTORY.  HEMAGEN WARRANTS THE PRODUCT AGAINST DEFECTS IN 
      MATERIAL AND WORKMANSHIP UNDER THE NORMAL USE AND SERVICE FOR WHICH IT 
      WAS DESIGNED, FOR THE SHELF LIFE PERIOD DEFINED IN APPENDIX A, 
      HEMAGEN'S OBLIGATION UNDER THIS WARRANTY BEING LIMITED TO THE 
      REPLACEMENT OF THE PRODUCT DETERMINED BY IT TO BE DEFECTIVE, PLUS 
      TRANSPORTATION COSTS FOR RETURN OF THE PRODUCT.  ALL REPLACEMENTS WILL 
      BE SHIPPED F.O.B. DISTRIBUTOR'S RECEIVING FACILITY.

Article 12  Confidentiality

12.1  Confidentiality.  For the purposes of this Agreement, the term 
      "Confidential Information" shall be any information embodying 
      concepts, ideas, techniques, know-how, formulations, market data, 
      customer lists, PRODUCT specifications and accounting data which:

      (a)   is disclosed by one party hereto to the other;
      (b)   is claimed by the disclosing party to be secret, 
            confidential and proprietary to the disclosing party; and
      (c)   if disclosed in writing, is marked by the disclosing party 
            to indicate its confidential nature or if disclosed 
            orally, is claimed in writing by the disclosing party to 
            be confidential within ten (10) days following disclosure. 

      During the period that this Agreement remains in effect and for a 
      period of three (3) years following termination hereof, each party 
      (except as is explicitly otherwise required hereby) shall keep 
      confidential, shall not use for itself or for the benefit of others 
      and shall not copy or allow to be copied in whole or in part any 
      Confidential Information disclosed to such party by the other.

      The obligations of confidentiality imposed upon the parties by the 
      foregoing paragraph shall not apply with respect to any alleged 
      Confidential Information which:

      (a)   is known to the recipient thereof, as evidenced by said 
            recipient's written records, prior to receipt thereof from the 
            other party hereto; 
      (b)   is disclosed to said recipient after the day hereof by a third 
            party who has the right to make such disclosure; or
      (c)   is or becomes a part of the public domain through no fault of 
            the said recipient. 

Article 13.  Termination

13.1. Termination For Cause.  Either party will have the right to terminate 
      this Agreement if the other party (a) assigns this Agreement or any 
      of its rights hereunder in violation of the provisions of Section 16.3 
      of this Agreement, or (b) becomes bankrupt or insolvent, or (c) makes 
      an assignment for the benefit of creditors, or a receiver, trustee in 
      bankruptcy or similar officer appointed to take charge of all or part 
      of its property, and such event has not been cured within thirty (30) 
      days of written notice thereof by the non-breaching party.  If either 
      party materially breaches this Agreement, including, but not limited 
      to, (a) DISTRIBUTOR's failure to adhere to the non-competition 
      requirements of Section 5.1,  (b) DISTRIBUTOR's failure to meet its 
      obligation regarding minimum annual purchases of PRODUCT, and (c) 
      either party's failure to adhere to the confidentiality provisions and 
      restrictions on use of information set forth in Section 12.1, then 
      notwithstanding any other provision of this Agreement, no cure period 
      shall be allowed and the non-breaching party shall be entitled to 
      terminate this Agreement immediately.

13.2. Termination Without Cause.  Either party shall have the right to 
      terminate this Agreement upon twelve (12) months written notice 
      without cause.

13.3. Rights and Obligations on Termination.  Upon termination of this 
      Agreement, DISTRIBUTOR shall immediately discontinue any previously 
      authorized use of any of HEMAGEN's Proprietary Rights and shall 
      immediately cease all conduct that might cause anyone to believe that 
      DISTRIBUTOR is authorized to market or sell PRODUCTs or otherwise 
      connected with HEMAGEN, and HEMAGEN may itself or through others, 
      commence sale, distribution and service of PRODUCTs in the TERRITORY.  
      Upon termination or expiration of this Agreement, DISTRIBUTOR will 
      immediately turn over to HEMAGEN all promotional and other materials 
      relating to HEMAGEN's PRODUCTs and shall immediately cease to 
      represent itself as authorized to market or sell PRODUCTs.

13.4. Termination or Expiration Damages.  Neither HEMAGEN nor DISTRIBUTOR 
      shall be liable to the other, or to any other business entity solely 
      by reason of the expiration or termination of this Agreement 
      regardless of the rationale for or propriety of any termination or 
      expiration.  The exculpation from liability shall be for any losses or 
      damages of any kind whatsoever, including, but not limited to, direct, 
      indirect, special, consequential or incidental damages sustained by 
      reason of such termination, including but not limited to, any claim 
      for loss of compensation or profits or for loss of prospective 
      compensation or prospective profits in respect of sales of any of the 
      PRODUCTs or on account of any expenditures, investments, leases, 
      capital improvements or any other commitments made by either party in 
      connection with their respective business made in reliance upon or by 
      virtue of this Agreement or otherwise.

13.5. Acknowledgment of Parties.  Each party hereto agrees that if this 
      Agreement is terminated rightfully and in good faith by the other 
      pursuant to the terms of this Agreement, the terminating party shall 
      not be liable to the other party for any termination compensation 
      whatsoever, whether based upon goodwill established, clientele 
      obtained, expenditures incurred, investments made, activities 
      undertaken or otherwise.  Termination of this Agreement for any reason 
      whatsoever shall not relieve either of the parties hereto from making 
      payment of monies due to the other from fulfilling obligations 
      incurred up to the effective date of termination or as otherwise 
      expressly provided in this Agreement.

13.6  Transfer of Importation License.  Upon termination of this Agreement, 
      DISTRIBUTOR shall transfer any government or regulatory license(s) or 
      permit(s), if any, which authorizes or approves the importation and 
      sale of PRODUCTs into the TERRITORY to HEMAGEN or its nominee.  

13.7. Termination of Distribution Rights in NON-EXCLUSIVE TERRITORY Without 
      Cause.  HEMAGEN shall have the right, upon three (3) months written 
      notice, without cause, to terminate  DISTRIBUTOR's distribution rights 
      in the NON-EXCLUSIVE TERRITORY.  Before exercising its right to 
      terminate DISTRIBUTOR's rights in the NON-EXCLUSIVE TERRITORY, HEMAGEN 
      must allow DISTRIBUTOR a thirty day (30) right to attempt to negotiate 
      with HEMAGEN for exclusive distribution rights in the NON-EXCLUSIVE 
      TERRITORY.   During such thirty day period, HEMAGEN and DISTRIBUTOR 
      shall negotiate in good faith.  Paragraphs 13.3, 13.4, 13.5 and 13.6 
      shall apply in the case that HEMAGEN exercises its rights to terminate 
      the NON-EXCLUSIVE TERRITORY.

Article 14  PRODUCT Recall and Regulatory Compliance

14.1. Data Base.  HEMAGEN and DISTRIBUTOR shall maintain a data base to 
      support all claims made or to be made regarding PRODUCTs' performance.

14.2  Inquiries.  Each party shall keep the other informed of any formal or 
      informal inquiry relating to PRODUCTs sold hereunder by any regulatory 
      agency of any state or national government.
 
14.3  PRODUCT Recall.  Should PRODUCT performance or any governmental action 
      require the recall or withholding from market of PRODUCTs sold by 
      HEMAGEN to DISTRIBUTOR, DISTRIBUTOR shall bear the costs and expenses 
      of recall if such recall is the result of any fault or omission 
      attributable to DISTRIBUTOR and HEMAGEN shall bear the costs and 
      expenses of recall if such recall is the result of any fault or 
      omission attributable to HEMAGEN.  Should such recall result from the 
      equal fault of both parties, or should it prove impossible to assign 
      fault to the satisfaction of both parties, the parties shall share the 
      said costs and expenses equally.

Article 15.  Arbitration

15.1. Any controversy or claim arising under or in relation to this 
      Agreement, except as otherwise expressly provided below, shall be 
      settled exclusively by arbitration in accordance with the 
      International Arbitration Rules of the American Arbitration 
      Association (AAA).  There shall be three arbitrators:  one selected by 
      HEMAGEN, one selected by DISTRIBUTOR, and one selected by the parties 
      jointly or, failing their agreement, selected pursuant to the rules of 
      the AAA.  The arbitration shall be conducted in English and shall be 
      held in Massachusetts.  The prevailing party shall be entitled to 
      recover its costs and attorneys' fees.  The decision of the 
      arbitrators shall be final and binding on the parties, and judgment 
      upon the award rendered by the arbitrators may be entered by any court 
      having jurisdiction thereof.  The provisions of this arbitration 
      clause shall not be applied to the determination of questions 
      affecting the validity or scope of any trademarks or other 
      intellectual property rights.

Article 16.  General Provisions

16.1  Antiboycott Compliance.  DISTRIBUTOR will not require or request 
      HEMAGEN to take any action or to provide any information in the 
      fulfillment of this Agreement which would cause HEMAGEN to violate the 
      antiboycott laws of the United States.
 
16.2. Entire Agreement.  This Agreement, including the Appendices, 
      constitutes the entire agreement between the parties with respect to 
      the subject matter hereof, and may not be modified (unless expressly 
      provided otherwise herein) except by a writing duly signed by both 
      parties. 

16.3. Assignment, Waiver, Severability.  Neither party may assign this 
      Agreement without the prior written consent of the other party.  
      Failure by either party to enforce any term hereof shall not be deemed 
      a waiver of future enforcement of that or any other term.  If any 
      provision of this Agreement is declared void or unenforceable by any 
      judicial, administrative or arbitration authority, such action will 
      not nullify the remaining provisions of this Agreement.

16.4. Governing Law.  This Agreement shall be governed and construed under 
      and according to the laws of the Commonwealth of Massachusetts, 
      U.S.A., excluding its choice of laws rules.  The Vienna Convention on 
      the International Sale of Goods is expressly excluded from 
      application.  

16.5. Relationship Created.  The relationship of the parties is that of 
      independent contractors.  Nothing in this Agreement shall be construed 
      as establishing an agency, joint venture or partnership between the 
      parties.  Each party is an independent entity, and shall have sole 
      responsibility for its employees, even while such employees are on the 
      premises of the other party's facility(ies).  Neither DISTRIBUTOR nor 
      HEMAGEN shall have the right to enter into any contracts or 
      commitments or to make any representations or warranties, whether 
      express or implied, in the name of or on behalf of any other party, or 
      to bind any other party in any respect whatsoever, unless agreed to in 
      writing or expressly permitted in this Agreement.

16.6. Authority.  Each party hereby represents and warrants that it has full 
      power and authority to enter into and perform this Agreement, without 
      any governmental approvals, and that its entering into and performance 
      of this Agreement will not conflict with any other agreement to which 
      it is a party or by which it is bound.

16.7. Notice.  Any written notice, or statement, necessary or appropriate 
      under this Agreement shall be deemed to be properly given if delivered 
      personally in writing or sent by registered or certified mail to the 
      party to be notified at the address set forth above or at such other 
      address as either party may hereafter designate in writing.

16.8. Captions.  The captions or paragraph headings of this Agreement do not 
      constitute any substantive part of this Agreement and shall not be 
      considered in the construction or interpretation of this Agreement.

16.9. Force Majeure.  Each party hereto shall be excused from the 
      performance of its obligations hereunder in the event such performance 
      is prevented by force majeure, and such excuse shall continue for so 
      long as the condition constituting such force majeure and any 
      consequences resulting from such condition continues.  In addition, in 
      the event the condition constituting the force majeure causes a 
      substantial inability by either party hereto to meet its obligations 
      hereunder, the term of this Agreement may, upon written agreement of 
      both parties, be suspended for the period of such inability, but not 
      to exceed six (6) months.  For the purposes of this Agreement, force 
      majeure shall mean causes beyond either party's control including, 
      without limitation, acts of God; regulations or laws of any 
      government; war, riot or civil commotion; damage to or destruction of 
      production facilities or materials by fire, earthquake, storm or other 
      disaster; manufacturing or transportation delay, strikes or other 
      labor disturbances, epidemic; and failure or default of public 
      utilities or common carriers.

IN CONSIDERATION OF the foregoing terms and conditions, DISTRIBUTOR and 
HEMAGEN have executed this Agreement on the day and year first written 
above.

HEMAGEN DIAGNOSTICS, INC.              SCHIAPPARELLI BIOSYSTEMS B.V.

/s/ Carl Franzblau                     /s/ J. J. H. Korten
    Carl Franzblau, President              J. J. H. Korten
HEMAGEN DIAGNOSTICS, INC.      SCHIAPPARELLI BIOSYSTEMS B.V.


                          Appendix 1.3 -- Territory

TERRITORY shall mean:

      Bangladesh
      Belgium
      Brunei
      Cyprus
      Turkey
      Czech Rep
      Denmark
      Egypt
      Finland
      Greece
      Hong Kong
      Iceland
      Jordan
      Korea
      Kuwait
      Lebanon
      Malaysia
      Malta
      Netherlands
      Norway
      Oman
      Pakistan
      Portugal
      Qatar
      Saudi Arabia
      Singapore
      South Africa
      Sweden
      Switzerland
      Syria
      Taiwan
      Thailand
      Tunisia
      Turkey
      United Arab Emirates
      Zimbabwe



Catalogue No.   Description                                      List Price 
 
 
                            Appendix A  -- Products 
 
 
AUTOIMMUNE DISEASE 
 
IMMUNOFLUORESCENCE ANTIBODY KITS 
 
 
ANTINUCLEAR (ANA) KB-SUBSTRATE 
 
902070          48 Determination Kit (IgG) 12 x 4-well slides 
902075          200 Determination Kit (IgG) 25 x 8-well slides 
902077          200 Determination Kit (IgG) 25 x 8-well slides 
 
COMPONENTS AND SLIDES 
 
902071          12 x 4-well slides 
902078-S        ANA Positive Control, 1 mL 
902076          25 x 8-well slides 
902079-S        Conjugate: FITC labeled goat anti-human  
                IgG(heavy and light chains) with  
                counterstain, 2 mL 
 
HEP-2 SUBSTRATE 
 
902332          200 Determination Kit (IgG) 25 x 8-well slides 
902360          600 Determination Kit (IgG) 50 x 12-well slides 
902370          1200 Determination Kit (IgG) 100 x 12-well slides 
 
ANTI-MITOCHONDRIAL (AMA)  
 
902080          48 Determination Kit (IgG) 12 x 4-well slides 
 
COMPONENTS AND SLIDES 
 
902090          12 x 4-well slides  
 
ANTI-nDNA (n-DNA) 
 
902409          48 Determination Kit (IgG) 6 x 8-well slides 
902420          96 Determination Kit (IgG) 12 x 8-well slides 
 
COMPONENTS AND SLIDE 
 
902408          6 x 8-well slides  
 
ELISA ANTIBODY KITS 
 
6630            ENA SCREENING - 6 
                96 wells for the simultaneous detection of  
                RNP, Sm, SS-A, SS-B, Scl-70 and Jo-1 
6601            ENA SCREENING - 4 
                96 wells for the simultaneous detection of  
                RNP, Sm, SS-A, and SS-B 
6641            ENA COMBI - 6  
                96 well kit.  Contains wells to test for  
                RNP, Sm, SS-A, SS-B, Scl-70 and Jo-1 
6640            ENA COMB - 4  
                64 well kit.  Contains wells to test for 
                RNP, Sm, SS-A and SS-B 
6607            Scl-70, 96 wells 
6608            Jo-1, 96 wells 
6611            Sm/RNP, 96 wells 
6612            Sm, 96 wells 
6614            SS-A, 96 wells 
6615            SS-B, 96 wells 
6613            Rheumatoid Factor, 96 wells* 
6621            dsDNA, 96 wells* 
6606            Anti-Cardiolipin, IgG and IgM, 96 wells 
6606A           Anti-Cardiolipin IgA Calibrator - reagents 
                for up to 48 wells 
                (designed to be used with catalogue #6606) 
 
HEMAGGLUTINATION KITS 
 
6420            ENA SCREENING - 4 
                64 Tests for the simultaneous detection 
                of RNP, Sm, SS-A and SS-B 
6401            RNP/Sm, 128 tests 
6403            RNP/Sm, 64 tests 
6415            SS-A/SS-B, 2x48 tests 
6412            Scl-70, 64 tests 
6417            Jo-1, 64 tests 
6407            dsDNA, 96 tests 
6413            RF, 192 tests 
 
 
INFECTIOUS DISEASE 
 
IMMUNOFLUORESCENCE ANTIBODY KITS 
 
 
TOXOPLASMA (TOXO) 
 
902010          120 Determination Kit (IgG) 15 x 8-well slides 
902020          200 Determination Kit (IgG) 25 x 8-well slides 
 
COMPONENTS AND SLIDES 
 
902019-S        Toxoplasma Negative Control (IgM), 0.5 mL 
902021          25 x 8-well slides   
902041          Conjugate: FITC labeled goat anti-human IgG 
                (heavy and light chains) with Evans Blue  
                counterstain, 2 mL 
902048          Conjugate: FITC labeled goat anti-human  
                IgM(mu-chain specific) with Evans Blue  
                counterstain 2.5 mL 
902049-S        Toxoplasma Positive Control (IgM), 0.5 mL 
 
CYTOMEGALOVIRUS (CMV)  
 
902111          96 Determination Kit (IgG) 12 x 8-well slides 
902112          96 Determination Kit (IgM) 12 x 8-well slides 
902113          200 Determination Kit (IgG) 25 x 8-well slides 
 
COMPONENTS AND SLIDES 
 
902114-S        Conjugate: FITC labeled goat anti-human IgG 
                (heavy and light chains) with counterstain, 2 mL 
902115-S        Conjugate: FITC labeled goat anti-human IgM 
                (mu-chain specific) with counterstain, 2 mL 
902117-S        CMV Positive Control (IgG), 1 mL 
902118-S        CMV Positive Control (IgM), 0.5 mL 
902120-S        CMV Negative Control (IgG), 1 mL 
902121-S        CMV Negative Control (IgM), 1 mL 
902123          12 x 8-well slides  
902124          25 x 8-well slides  
 
FLUORESCENT TREPONEMAL ANTIBODY-ABSORPTION (FTA-ABS)  
 
902300          60 Determination Kit (IgG) 15 x 4-well slides 
902301          200 Determination Kit (IgG) 25 x 8-well slides 
 
COMPONENTS AND SLIDES 
 
902304          25 x 8-well slides  
902309-S        FTA-ABS Sorbent, 10 mL 
 
HERPES SIMPLEX VIRUS TYPE I (HSV1) 
 
902500          96 Determination Kit (IgG) 12 x 8-well slides 
902506          200 Determination Kit (IgG) 25 x 8-well slides 
 
COMPONENTS AND SLIDES 
 
902501          12 x 8-well slides  
902504-S        Conjugate: FITC labeled goat anti-human IgG 
                (heavy and light chains) with counterstain, 2 mL 
902507          25 x 8-well slides 
 
HERPES SIMPLEX VIRUS TYPE 2 (HSV2) 
 
902600          96 Determination Kit (IgG) 12 x 8-well slides 
902606          200 Determination Kit (IgG) 25 x 8-well slides 
 
COMPONENTS AND SLIDES 
 
902601          12 x 8-well slides  
902607          25 x 8-well slides  
 
RUBELLA  
 
902700          96 Determination Kit (IgG) 12 x 8-well slides 
 
COMPONENTS AND SLIDES 
 
902701          12 x 8-well slides  
 
VARICELLA-ZOSTER (VZV) 
 
902800          96 Determination Kit (IgG) 12 x 8-well slides 
 
COMPONENTS AND SLIDES 
 
902801          12 x 8-well slides  
902804-S        Conjugate: FITC labeled goat anti-human IgG  
                (heavy and light chains) with counterstain, 2 mL 
 
EPSTEIN-BARR VIRUS (EBV) VCA  
 
902900          96 Determination Kit (IgG) 12 x 8-well slides 
 
COMPONENTS AND SLIDES 
 
902901          12 x 8-well slides  
 
CHLAMYDIA TRACHOMATIS 
 
903000          96 Determination Kit (IgG) 12 x 8-well slides 
 
COMPONENTS AND SLIDES 
 
903001          12 x 8-well slides  
 
903004-S        Conjugate: FITC labeled goat anti-human IgG 
                (heavy and light chains) with counterstain, 2 mL 
 
MEASLES  
 
903100          96 Determination Kit 12 x 8-well slides 
 
COMPONENTS AND SLIDES 
 
903101          12 x 8-well slides  
903104-S        Conjugate: FITC labeled goat anti-human IgG 
                (heavy and light chains), 2 mL 
 
MUMPS  
 
903200          96 Determination Kit (IgG) 12 x 8-well slides 
 
COMPONENTS AND SLIDES 
 
903201          12 x 8-well slides  
 
RESPIRATORY SYNCYTIAL VIRUS (RSV) 
 
903300          96 Determination Kit (IgG) 12 x 8-well slides 
 
COMPONENTS AND SLIDES 
 
903301          12 x 8-well slides  
 
6637            Herpes I  96 wells 
6638            Herpes II  96 wells 
 
 
UNIVERSAL IFA COMPONENTS 
 
903405          IFA Buffer (5 packs - sufficient for 5 liters) 
902083          Buffered Glycerol, 4 x 2 mL vials 
902200-S        Universal IgM Conjugate 
 
 
ACUTE PHASE REACTANT KITS 
 
6602            Serum Amyloid A (EIA), 96 wells* 
6605            C-Reactive Protein (EIA), 96 wells 
 
 
Human Interleukin-2 
T-Cell Growth Factor 
 
906011          50 mL Bottle 
 
*   Available For Export and/or Research Use Only.  Call for availability. 
 
 
Shelf Life 
 
Minimum shelf life for PRODUCTs is 8 months from date of expiration.



                             Appendix B - Terms 
 
 
1.  HEMAGEN grants to DISTRIBUTOR marketing rights to sell PRODUCTs in the  
    TERRITORY. 
 
2.  Minimum orders for the initial term are listed below. 
 
                                               Purchase Minimums 
                   Year 1                      $250,000 
                   Year 2                      $350,000 
                   Year 3                      $450,000

3.  Orders are shipped F.O.B. Waltham, Massachusetts or Columbia, Maryland  
    (depending on place of manufacture); payment terms are U.S. dollars net  
    60 days.  Any cost or chargers for currency conversion shall be borne by  
    DISTRIBUTOR. 
 
4.  Should HEMAGEN and DISTRIBUTOR elect to extend the Agreement beyond the  
    initial term as provided in Article 2, new minimums, not lower than  
    those set for the previous year, will be established by mutual  
    agreement. 



Catalog No.     Description                                     List Price 
 
                             Appendix C - PRICES 
 
 
AUTOIMMUNE DISEASE 
 
IMMUNOFLUORESCENCE ANTIBODY KITS 
 
 
ANTINUCLEAR (ANA) KB-SUBSTRATE 
 
902070          48 Determination Kit (IgG) 12 x 4-well slides   CONFIDENTIAL 
                                                                TREATMENT  
                                                                REQUESTED 
902075          200 Determination Kit (IgG) 25 x 8-well slides  CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902077          200 Determination Kit (IgG) 25 x 8-well slides  CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
COMPONENTS AND SLIDES 
 
902071          12 x 4-well slides                              CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902078-S        ANA Positive Control, 1 mL                      CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902076          25 x 8-well slides                              CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902079-S        Conjugate: FITC labeled goat anti-human IgG     CONFIDENTIAL 
                (heavy and light chains) with counterstain,     TREATMENT 
                2 mL                                            REQUESTED  
 
HEP-2 SUBSTRATE 
 
902332          200 Determination Kit (IgG) 25 x 8-well slides  CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902360          600 Determination Kit (IgG) 50 x 12-well slides CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902370          1200 Determination Kit (IgG) 100 x 12-well      CONFIDENTIAL 
                slides                                          TREATMENT  
                                                                REQUESTED 
902330          48 Determination Kit (IgG) 12 x 4 well slides   CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
COMPONENTS AND SLIDES 
 
902331          12 x 4 well Slides Hep-2 substrate              CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902333          25 x 8 well Slides Hep-2 Substrate              CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
ANTI-MITOCHONDRIAL (AMA)  
 
902080          48 Determination Kit (IgG) 12 x 4-well slides   CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
COMPONENTS AND SLIDES 
 
902090          12 x 4-well slides                              CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
ANTI-nDNA (n-DNA) 
 
902409          48 Determination Kit (IgG) 6 x 8-well slides    CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902420          96 Determination Kit (IgG) 12 x 8-well slides   CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
COMPONENTS AND SLIDE 
 
902408          6 x 8-well slides                               CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
ELISA ANTIBODY KITS 
 
6630            ENA SCREENING - 6                               CONFIDENTIAL 
                96 wells for the simultaneous detection         TREATMENT 
                of RNP, Sm, SS-A, SS-B, Scl-70 and Jo-1         REQUESTED 
6601            ENA SCREENING - 4                               CONFIDENTIAL 
                96 wells for the simultaneous detection         TREATMENT 
                of RNP, Sm, SS-A, and SS-B                      REQUESTED 
6641            ENA COMBI - 6                                   CONFIDENTIAL 
                96 well kit.  Contains wells to test for        TREATMENT 
                RNP, Sm, SS-A, SS-B, Scl-70 and Jo-1            REQUESTED 
6640            ENA COMB - 4                                    CONFIDENTIAL 
                64 well kit.  Contains wells to test for        TREATMENT 
                RNP, Sm, SS-A and SS-B                          REQUESTED 
6607            Scl-70, 96 wells                                CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
6608            Jo-1, 96 wells                                  CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
6611            Sm/RNP, 96 wells                                CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
6612            Sm, 96 wells                                    CONFIDENTIAL 
                                                                TREATMENT  
                                                                REQUESTED 
6614            SS-A, 96 wells                                  CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
6615            SS-B, 96 wells                                  CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
6613            Rheumatoid Factor, 96 wells*                    CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
6621            dsDNA, 96 wells*                                CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
6606            Anti-Cardiolipin, IgG and IgM, 96 wells         CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
6606A           Anti-Cardiolipin IgA Calibrator - reagents      CONFIDENTIAL 
                for up to 48 wells                              TREATMENT 
                (designed to be used with catalogue #6606)      REQUESTED 
 
HEMAGGLUTINATION KITS 
 
6420            ENA SCREENING - 4                               CONFIDENTIAL 
                64 Tests for the simultaneous detection         TREATMENT 
                of RNP, Sm, SS-A and SS-B                       REQUESTED 
6401            RNP/Sm, 128 tests                               CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
6403            RNP/Sm, 64 tests                                CONFIDENTIAL 
                                                                TREATMENT  
                                                                REQUESTED 
6415            SS-A/SS-B, 2x48 tests                           CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
6412            Scl-70, 64 tests                                CONFIDENTIAL 
                                                                TREATMENT  
                                                                REQUESTED 
6417            Jo-1, 64 tests                                  CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
6407            dsDNA, 96 tests                                 CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
6413            RF, 192 tests                                   CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
INFECTIOUS DISEASE 
 
IMMUNOFLUORESCENCE ANTIBODY KITS 
 
TOXOPLASMA (TOXO) 
 
902010          120 Determination Kit (IgG) 15 x 8-well slides  CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902020          200 Determination Kit (IgG) 25 x 8-well slides  CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
COMPONENTS AND SLIDES 
 
902019-S        Toxoplasma Negative Control (IgM), 0.5 mL       CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902021          25 x 8-well slides                              CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902041          Conjugate: FITC labeled goat anti-human IgG     CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
                (heavy and light chains) with Evans Blue counterstain, 2 mL 
902048          Conjugate: FITC labeled goat anti-human         CONFIDENTIAL 
                IgM(mu-chain specific) with Evans Blue          TREATMENT 
                counterstain 2.5 mL                             REQUESTED 
902049-S        Toxoplasma Positive Control (IgM), 0.5 mL       CONFIDENTIAL 
                                                                TREATMENT  
                                                                REQUESTED 
 
CYTOMEGALOVIRUS (CMV)  
 
902111          96 Determination Kit (IgG) 12 x 8-well slides   CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902112          96 Determination Kit (IgM) 12 x 8-well slides   CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902113          200 Determination Kit (IgG) 25 x 8-well slides  CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
COMPONENTS AND SLIDES 
 
902114-S        Conjugate: FITC labeled goat anti-human IgG     CONFIDENTIAL 
                (heavy and light chains) with counterstain,     TREATMENT 
                2 mL                                            REQUESTED 
902115-S        Conjugate: FITC labeled goat anti-human IgM     CONFIDENTIAL 
                (mu-chain specific) with counterstain, 2 mL     TREATMENT 
                                                                REQUESTED 
902117-S        CMV Positive Control (IgG), 1 mL                CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902118-S        CMV Positive Control (IgM), 0.5 mL              CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902123          12 x 8-well slides                              CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902124          25 x 8-well slides                              CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
FLUORESCENT TREPONEMAL ANTIBODY-ABSORPTION (FTA-ABS)  
 
902300          60 Determination Kit (IgG) 15 x 4-well slides   CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902301          200 Determination Kit (IgG) 25 x 8-well slides  CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
COMPONENTS AND SLIDES 
 
902304          25 x 8-well slides                              CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902309-S        FTA-ABS Sorbent, 10 mL                          CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
HERPES SIMPLEX VIRUS TYPE I (HSV1) 
 
902500          96 Determination Kit (IgG) 12 x 8-well slides   CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902506          200 Determination Kit (IgG) 25 x 8-well slides  CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
COMPONENTS AND SLIDES 
 
902501          12 x 8-well slides                              CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902504-S        Conjugate: FITC labeled goat anti-human IgG     CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
                (heavy and light chains) with counterstain, 2 mL 
902507          25 x 8-well slides                              CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
HERPES SIMPLEX VIRUS TYPE 2 (HSV2) 
 
902600          96 Determination Kit (IgG) 12 x 8-well slides   CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902606          200 Determination Kit (IgG) 25 x 8-well slides  CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
COMPONENTS AND SLIDES 
 
902601          12 x 8-well slides                              CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902607          25 x 8-well slides                              CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
RUBELLA  
 
902700          96 Determination Kit (IgG) 12 x 8-well slides   CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
COMPONENTS AND SLIDES 
 
902701          12 x 8-well slides                              CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
VARICELLA-ZOSTER (VZV) 
 
902800          96 Determination Kit (IgG) 12 x 8-well slides   CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
COMPONENTS AND SLIDES 
 
902801          12 x 8-well slides                              CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
902804-S        Conjugate: FITC labeled goat anti-human IgG     CONFIDENTIAL 
                (heavy and light chains) with counterstain,     TREATMENT 
                2 mL                                            REQUESTED 
 
EPSTEIN-BARR VIRUS (EBV) VCA  
 
902900          96 Determination Kit (IgG) 12 x 8-well slides   CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
COMPONENTS AND SLIDES 
 
902901          12 x 8-well slides                              CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
CHLAMYDIA TRACHOMATIS 
 
903000          96 Determination Kit (IgG) 12 x 8-well slides   CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
COMPONENTS AND SLIDES 
 
903001          12 x 8-well slides                              CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
903004-S        Conjugate: FITC labeled goat anti-human IgG     CONFIDENTIAL 
                (heavy and light chains) with counterstain,     TREATMENT 
                2 mL                                            REQUESTED 
 
MEASLES  
 
903100          96 Determination Kit 12 x 8-well slides         CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
COMPONENTS AND SLIDES 
 
903101          12 x 8-well slides                              CONFIDENTIAL 
                                                                TREATMENT  
                                                                REQUESTED 
 
903104-S        Conjugate: FITC labeled goat anti-human IgG     CONFIDENTIAL 
                (heavy and light chains), 2 mL                  TREATMENT 
                                                                REQUESTED 
 
MUMPS  
 
903200          96 Determination Kit (IgG) 12 x 8-well slides   CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
COMPONENTS AND SLIDES 
 
903201          12 x 8-well slides                              CONFIDENTIAL 
                                                                TREATMENT  
                                                                REQUESTED 
 
RESPIRATORY SYNCYTIAL VIRUS (RSV) 
 
903300          96 Determination Kit (IgG) 12 x 8-well slides   CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
COMPONENTS AND SLIDES 
 
903301          12 x 8-well slides                              CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
UNIVERSAL IFA COMPONENTS 
 
903405          IFA Buffer (5 packs - sufficient for 5 liters)  CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902083          Buffered Glycerol, 4 x 2 mL vials               CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
902200-S        Universal IgM Conjugate                         CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
ACUTE PHASE REACTANT KITS 
 
6602            Serum Amyloid A (EIA), 96 wells*                CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
6605            C-Reactive Protein (EIA), 96 wells              CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED 
 
Human Interleukin-2 
 
T-Cell Growth Factor 
 
906011          50 mL Bottle                                    CONFIDENTIAL  
                                                                TREATMENT  
                                                                REQUESTED